N/A N=36 Potato Research for Enhancing Metabolic Outcomes
Insulin Resistance · Obesity
Primary: Glycemic Response to the Diet — -103.44; -501.91 mg/dL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=40 CogT BEEM Study (a tDCS Study)
Mild Cognitive Impairment · Neuropsychiatric Syndrome
Primary: Change of C3 Activation (NPS-shared Neural Circuit Measure — -0.15; 0.01 change of arbitrary unit LPG activation — p=<0.05
N/A N=66 Clinical Evaluation of Delefilcon A and Verofilcon A Daily Disposable Toric Soft Contact Lenses Over One Week of Wear
Ocular Physiology
Primary: Percentage of Eyes With Grade 3 or Higher Slit Lamp Findings — 0; 0 Percent
Phase 3 N=440 A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder
Depressive Disorder, Major
Primary: Change From Baseline in the HAMD-17 Total Score at Day 3 — -7.0; -8.9 score on a scale — p=0.0004
N/A N=46 Continuous And Pulsed Ultrasound Treatments On Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
Primary: Change From Baseline in Symptom Severity With Symptom Severity Scale — 23.06; 22.06; 19.66 units on a scale — p=0.442
N/A N=129 Reducing Pain and Disability After Breast Cancer Surgery
Breast Cancer · Chronic Pain
Primary: The Proportion of Individuals Reporting Chronic Postoperative Pain 12 Months Following Breast Cancer Surgery With Lymph Node Dissection. — 5; 4 Participants
Early Phase 1 N=14 Measuring the Neuroimmune Response to Alcohol
Alcohol Drinking
Primary: Percent Change in [11C]PBR28 Distribution Volume After Alcohol Challenge. — 15.79; 6.36 [11C]PBR28 VT (% change)
Phase 2 N=51 Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
Chronic Hepatitis B
Primary: Mean Change in Quantitative Hepatitis B Surface Antigen (qHBsAg) — 0.0; 0.0; 0.0; 0.0 log10 IU/mL — p=1.000
N/A N=34 Cognitive Aspects of Response to Treatment for Weight-related Health to Improve Eating and Exercise Earlier in Life
Pediatric Obesity · Executive Function
Primary: Change From Baseline Child Body Fat Mass at 6 Months — -.96 %bf tblh (total body less head)
Phase 2 N=13 Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Acinar Cell Adenocarcinoma of the Pancreas · Duct Cell Adenocarcinoma of the Pancreas · Stage IV Pancreatic Cancer
Primary: Maximum Tolerated Dose (MTD) of Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-stabilized Nanoparticle Formulation Combination (Phase Ib) — 80 milligrams
Phase 2 N=40 Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
COVID-19
Primary: Day 28 Ventilator Free Survival — 0.79; 0.86 proportion of participants
Phase 1 N=24 A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
Hepatic Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Mobocertinib and Its Active Metabolites (AP32960 and AP32914) — 9.67; 11.3; 10.5; 3.88 nanograms per milliliter (ng/mL)
Phase 1 N=23 A Study of Pevonedistat in Adult East Asian Participants
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 7; 3; 10 Participants
Phase 2 N=20 Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT
Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Incidence of Relapse — 30 Percentage of participants
N/A N=10 Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
Cardiac Toxicity · Chemotherapeutic Agent Toxicity · Lymphoma
Primary: Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy — 5; 5 Participants